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Introduction: Stem cell-based therapies are currently widely explored as a tool to treat neuroimmune diseases.
Multipotent adult progenitor cells (MAPC) have been suggested to have strong immunomodulatory and
neuroprotective properties in several experimental models. In this study, we investigate whether MAPC are of
therapeutic interest for neuroinflammatory disorders such as multiple sclerosis by evaluating their capacities to
modulate crucial pathological features and gain insights into the molecular pathways involved.
Methods: Rat MAPC were treated with combinations of pro-inflammatory cytokines that are closely associated with
neuroinflammatory conditions, a process called licensing. mRNA expression of immunomodulatory molecules,
chemokines and chemokine receptors was investigated. The migratory potential of licensed rat MAPC towards a
broad spectrum of chemokines was tested in a Transwell assay. Furthermore, the effect of licensing on the ability of
rat MAPC to attract and suppress the proliferation of encephalitogenic T cells was assessed. Finally, neuroprotective
properties of rat MAPC were determined in the context of protection from oxidative stress of oligodendrocytes.
Therefore, rat MAPC were incubated with conditioned medium of OLN93 cells subjected to sublethal doses of
hydrogen peroxide and the gene expression of neurotrophic factors was assessed.
Results: After licensing, a wide variety of immunomodulatory molecules and chemokines, including inducible nitric
oxide synthase and fractalkine, were upregulated by rat MAPC. The migratory properties of rat MAPC towards
various chemokines were also altered. In addition, rat MAPC were found to inhibit antigen-specific T-cell
proliferation and this suppressive effect was further enhanced after pro-inflammatory treatment. This phenomenon
was partially mediated through inducible nitric oxide synthase or cyclooxygenase-2. Activated rat MAPC secreted
factors that led to attraction of myelin-specific T cells. Finally, exposure of rat MAPC to an in vitro simulated
neurodegenerative environment induced the upregulation of mRNA levels of vascular endothelial growth factor
and ciliary neurotrophic factor. Factors secreted by rat MAPC in response to this environment partially protected
OLN93 cells from hydrogen peroxide-induced cell death.
Conclusions: Rat MAPC possess immune modulatory and neuroprotective properties which are enhanced in
response to neuroinflammatory signals. These findings thereby warrant further research to evaluate MAPC
transplantation as a therapeutic approach in diseases with an immunological and neurodegenerative component
such as multiple sclerosis.* Correspondence: niels.hellings@uhasselt.be
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Stem cell transplantation represents a promising thera-
peutic approach to treat neuroinflammatory and neurode-
generative disorders. By using experimental murine models
of neuroinflammatoy diseases, such as experimental auto-
immune encephalomyelitis (EAE), traumatic brain injury
(TBI) and spinal cord injury (SCI), several studies demon-
strated that stem cells reduce neurological deterioration
and protect the central nervous system (CNS) from fur-
ther damage and even stimulate its repair [1–7]. In these
studies both adult-derived bone marrow mesenchymal
stem cells (MSCs) and newborn CNS-derived neural stem
cells (NSCs) provided neurotrophic support and even re-
placed damaged oligodendrocytes and neurons [3–5]. Of
note, the therapeutic action of transplanted cells did not
relate to the route of administration—peripheral- or CNS-
directed. In addition to the neuroprotective and regenera-
tive potential, the immunomodulatory properties of NSCs
and MSCs have been well established [1, 2, 8]. NSCs
and MSCs were found to suppress the reactivity of en-
cephalitogenic T cells in the EAE model, thereby likely
ameliorating pathological features and clinical symp-
toms. Collectively, these findings indicate that stem cells
can not only halt neuroinflammation but also stimulate
CNS repair upon inflammatory neurodegeneration.
These properties make them an interesting tool for the
treatment of all pathophysiological facets of multiple
sclerosis (MS). However, the use of CNS-derived NSCs
for autologous transplantation is not a feasible option.
Furthermore, although MSCs have been used in clinical
trials for autoimmune diseases, the signs of replicative
senescence that are demonstrated remain an obstacle
for their use as a large-scale clinical product [9–13].
In 2002, another bone marrow-derived stem cell popu-
lation of mesenchymal origin was initially described,
named multipotent adult progenitor cells (MAPC) [14].
Interestingly, in contrast to MSCs, MAPC do not show
signs of replicative senescence and possess broader expan-
sion capacities [9–11, 14]. MAPC, in contrast to MSCs,
have an extensive differentiation potential towards cell
types of all three germ layers depending on the expression
levels of pluripotency genes such as oct-4 [14–16]. Import-
antly, recent studies indicate that MAPC have neuropro-
tective and immunosuppressive properties. Rat MAPC
(rMAPC) were found to preserve hippocampal cell loss in
an animal model of hypoxia-ischemia [17], while human
MAPC (hMAPC) stimulated recovery in an animal model
of TBI, likely through splenocyte-triggered modulation
of microglia phenotype [18–20]. Yet other studies re-
vealed that murine MAPC (mMAPC) attenuate allor-
eactive T-cell proliferation [21] while hMAPC suppress
natural killer (NK) cell proliferation in an indoleamine
2,3-dioxygenase 1 (Ido-1)-dependent manner [22]. There-
fore, while MAPC possess intrinsic immune modulatingand neuroprotective properties, they show superior fea-
tures over MSCs, such as the broader expansion rate with-
out any obvious genetic abnormalities [9, 14]. These
features make MAPC a more attractive candidate for po-
tential stem cell transplantation therapies in CNS disor-
ders, such as MS, TBI and SCI.
In this study, we defined the therapeutic potential of
MAPC in neuroinflammatory diseases. For this purpose,
we determined the basal immunomodulatory, migratory,
chemoattractive and neuroprotective features of rMAPC.
Next, the impact of pro-inflammatory and neurodegenera-
tive stimuli on the physiology of rMAPC was assessed. It
was previously reported that a pro-inflammatory milieu
markedly alters the physiology of stem cells (a process
called ‘licensing’) [23–26]. rMAPC were licensed with
combinations of interferon gamma (IFNγ), tumor necrosis
factor alpha (TNFα) and interleukin-1 beta (IL1β). These
cytokines are highly expressed in the brain parenchyma
and cerebrospinal fluid in CNS neuroinflammatory dis-
eases and play a crucial role in their pathophysiology. Par-
ticularly, IFNγ secreted by Th1 cells leads to the activation
of other immune cells whereas TNFα and IL1β secreted
by activated macrophages and microglia lead to direct de-
struction of myelin sheath and oligondendrocytes [27–30].
We show that unstimulated rMAPC possess immuno-
modulatory and neuroprotective properties which are fur-
ther enhanced when challenged with neuroinflammatory
signals. Specifically, rMAPC suppressed autoreactive T-
cell proliferation and protected oligodendrocytes from
hydrogen peroxide (H2O2)-induced damage. We further
present that licensing increases the capacity of rMAPC to
attract T cells, while they themselves adopt an enhanced
migratory profile. Collectively these findings show that
rMAPC, when challenged in vitro with signals that are
overexpressed in a neuroinflammatory environment, ac-
quire a phenotype which may limit disease activity in vivo.
Materials and methods
rMAPC culture and inflammatory licensing
Lewis rMAPC and culture medium were provided by
ReGenesys (Leuven, Belgium). rMAPC were isolated and
maintained according to a previously described protocol
[15]. Briefly, bone marrow from tibiae and femur from
Lewis rats was excised and flushed using phosphate-
buffered saline (PBS; Lonza, Verviers, Belgium). The single
cell suspension was centrifuged and washed using rMAPC
medium. rMAPC medium consisted of 60 % Dulbecco’s
modified Eagle's medium (DMEM; Gibco, Life Technolo-
gies Europe B.V., Gent, Belgium) low glucose (1 g/l) , 40 %
MCDB-201 medium (pH 7.2), 1× linoleic acid-bovine
serum albumin (BSA), 10−4 M L-Ascorbic acid, 0.05 μM
dexamethasone, 55 μM 2-mercapto-ethanol (all from
Sigma Aldrich, Diegem, Belgium), 100 IU/ml penicillin
and 100 μg/ml streptomycin (Invitrogen, Life Technologies
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ng/ml mouse epidermal growth factor, 10 ng/ml recombin-
ant human platelet-derived growth factor (R & D systems,
Abingdon, United Kingdom), 2 % fetal bovine serum
(Hyclone, EU approved, Cat CH30160.03), and 103 units/
ml mouse leukemia inhibitory factor (Millipore). Cells were
seeded in fibronectin (10 ng/ml; Sigma Aldrich) coated
plates for 1 month in increasing densities. After 1 month of
culturing, negative control selection was performed to elim-
inate CD45+ hematopoietic cells. The resulted cell fraction
was subcloned until a homogeneous population of small,
spindle-shaped cells remained. The cells with MAPC
morphology were maintained in culture in order for col-
onies to be formed. Frozen stock was created with cells in
medium containing rMAPC medium, fetal bovine serum
and dimethyl sulfoxide (DMSO). Cells were maintained in
T175 flasks (Cellstar, Greiner Bio-One, Vilvoorde, Belgium)
or petri dishes (Nunc, VWR, Leuven, Belgium) according
to the purposes needed and maintained at 37 °C/5 % O2.
All experiments were performed with rMAPC that reached
10 population doublings maximum.
To assess the impact of pro-inflammatory treatment
(licensing) on rMAPC properties, cells were treated with
100 ng/ml of combinations of rat recombinant cytokines
(IFNγ + TNFα, IFNγ + IL1β, TNFα + IL1β; all from
Peprotech, London, UK) or PBS as vehicle control for 12
or 24 hours. Specific licensing incubation times are de-
scribed in each section.
Colony forming unit fibroblast assay
Cells were seeded as 10 cells/cm2 in six-well plates.
Medium was changed every 2 days. After 12 days,
medium was removed and cells were fixed with 4 %
paraformaldehyde (PFA) for 20 minutes and then were
washed twice with PBS. A solution of 0.5 % crystal vio-
let (Sigma Aldrich) in methanol was added for 30 mi-
nutes. Following the incubation time, cells were
washed three times with PBS, rinsed with tap water
and allowed to air dry before measuring the colonies.
To explore the impact of licensing on the ability of
rMAPC to form colonies, cells were pre-treated for 24
hours with the three combinations of cytokines and
vehicle.
Flow cytometry
Cells were detached with 0.25 % trypsin (Gibco), har-
vested and washed with fluorescence-activated cell sort-
ing (FACS) buffer (PBS supplemented with 2 % fetal calf
serum (FCS; Gibco)) and incubated in the dark for 30
minutes at 4 °C with surface antibodies. Phenotypic ana-
lysis of the cells was performed using CD11b/c, CD31
(BD Biosciences, Erembodegem, Belgium), CD44 (Immu-
notools, Friesoythe, Germany), CD80, CD86 (eBioscience,
Vienna, Austria), RT-1a and RT-1b (Biolegend, San Diego,CA, USA). Cells were positive for CD44 and RT-1a,
expressed low to negligible levels of CD80, while they
were completely negative for CD11b/c, CD31, CD86 and
RT-1b.
Generation of myelin basic protein-specific T cells
Myelin basic protein (MBP)-specific T cells were isolated
as described previously [31]. Briefly, 8-week-old female
Lewis rats (Janvier, France) were injected subcutaneously
with a 0.1 ml solution of 250 μg/ml guinea pig MBP, 2.5
mg/ml H37RA heat-killed mycobacterium tuberculosis
(Difco, Detroit, USA) and 60 μl Complete Freund’s adju-
vant (Sigma Aldrich) in both hind paws. Ten days post-
immunization, popliteal and inguinal lymph nodes were
removed and single cell suspensions were obtained by
grinding the tissues through a 70 μm cell strainer with a
syringe plunger. The isolated cells were seeded initially
in T cell medium consisting of RPMI-1640 medium, 1 %
penicillin-streptomycin mixture, 1 % non-essential amino
acids, 1 % sodium pyruvate (all from Invitrogen, Life
Technologies Europe B.V.), 20 μM 2-mercapto-ethanol
(Sigma Aldrich) supplemented with 2 % heat-inactivated
autologous serum and 33 μg/ml MBP. After 48 hours, T
cells were collected, washed and seeded in T cell medium
supplemented with 10 % FCS (Gibco) and 6.5 % CAS
medium (supernatant of Concanavalin A (Sigma Aldrich)
activated spleen cells) for another 48 hours. Next, cells
were collected, washed and seeded in T cell medium sup-
plemented with 10 % FCS for 3 days. All animal experi-
ments were approved by the Ethical Committee for
Animal Experiments of Hasselt University.
Co-cultures
Prior to co-culture with rMAPC, T cells were labeled
with 4 μM carboxyfluorescein diacetatesuccinimidyl
ester (CFSE; Invitrogen) at a concentration of 2 × 107
cells/ml in PBS/0.1 % BSA (Millipore, Merck Chemicals
N.V./S.A., Overijse, Belgium) solution. CFSE-labeled T
cells (7.5 × 104 cells/ well) were seeded alongside rMAPC
in ratios ranging from 1:0.5 to 1:2 (T cells/rMAPC). Ir-
radiated thymocytes (7.5 × 104 cells/well, 3000 rad) were
added to each well as antigen-presenting cells. The
medium of the co-cultures consisted of a 1:1 mixture of
rMAPC medium and T cell medium with 2 % autolo-
gous serum supplemented with 10 μg/ml MBP. To
explore the effect of licensing on their suppressive cap-
acity, rMAPC were pre-treated with the three combina-
tions of cytokines and vehicle for 12 hours prior to the
co-culture. To define the involvement of nitric oxide
(NO), cyclooxygenase (COX)-2 and Ido-1 in suppressive
activity, respectively 1.5 mM L-NG-monomethyl argin-
ine citrate (L-NMMA;VWR), 10 μM indomethacin
(Sigma Aldrich) and 200 μM 1-methyl-L-tryptophan/
1-methyl-D-tryptophan (1-Mt-L and 1-Mt-D; Sigma
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After 4 days, flow cytometry was used to assess prolifer-
ation and cell death of lymphocytes. Therefore, cells
were stained with phycoerythrin-conjugated mouse
anti-rat CD3 (eBioscience) and 7 aminoactinomycin D
(7AAD; BD Biosciences). T-cell proliferation was deter-
mined based on CFSE dye dilution of CD3+7AAD− cells
using flow cytometry (FACSCalibur).
Migration assays
To explore the chemoattractive properties of rMAPC,
we seeded MBP-specific T cells (2.5 × 105 cells/insert) in
the upper chamber of a transwell plate with a 5-μm pore
size (Sigma Aldrich). In the bottom chamber super-
natant of (licensed) rMAPC was placed. To obtain the
supernatants, rMAPC were seeded in a mixture of media
(30 % MAPC medium, 70 % RPMI-1640) and licensed
for 24 hours with respective cytokine combinations. The
supernatant was aspirated and filtered through a 0.45-μm
filter. Following 4 hours of culture at 37 °C, migrated cells
were collected from the bottom chamber and counted
using a hemocytometer. Non-conditioned medium served
as negative control.
To explore the functionality of chemokine receptors
expressed by rMAPC, rat recombinant CCL2, CCL5,
CX3CL1, CXCL10 and CXCL12α (100, 250 and 500 ng/ml,
all from Peprotech) were administered in the bottom
chamber of a transwell plate with an 8-μM pore size
(Sigma Aldrich). Cells were seeded in the upper chamber
at a concentration of 5 × 104 cells/insert and allowed to
migrate for 16 hours. Recombinant chemokines were di-
luted in DMEM-low glucose 1 g/l (Gibco). DMEM (glu-
cose 1 g/l) was used as negative control. As a positive
control, rMAPC medium (ReGenesys) was used, as it
was optimized to be more effective than the more
traditionally used FCS containing solutions (20 % FCS
in DMEM 1 g/l solution (see Additional file 1)). To
explore the impact of inflammatory conditions on the
migration profile of rMAPC, cells were licensed for
12 hours before allowing them to migrate. For the
quantification of the migrated fraction we used a
protocol by Bronckaers et al. [32] with minor modifi-
cations. Briefly, cells on both sides of the insert were
fixed with 4 % PFA solution for 20 minutes. Following
one washing step with PBS, cells were incubated with
0.1 % crystal violet (Sigma Aldrich) solution in etha-
nol for 10 minutes at room temperature. Next, cells
on the top side of the insert were removed with a cot-
ton swab and an additional washing step with PBS
was performed. Wells were allowed to air dry; there-
after, two pictures from each well were taken. Finally,
the migrated fraction was analyzed using ImageJ soft-
ware and expressed as percentage of the total covered
area [33].OLN93 cell culture, generation of conditioned media and
protection assays
The OLN93 cell line was a kind gift from Prof. Dr. C.
Richter-Landsberg (University of Oldenburg). Cells were
cultured in DMEM high glucose (Sigma Aldrich) supple-
mented with 10 % FCS and 1 % penicillin-streptomycin
mixture at 37 °C/10 % CO2. Conditioned media from
rMAPC were prepared according to the protocol of Isele
et al. [34] with minor modifications. An illustration of
the protocol is depicted in Additional file 2. Briefly,
OLN93 were seeded in a 96-well flat bottom plate (Greiner
Bio-One) (5 × 104 cells/well) and then treated with 1 mM
H2O2 to induce sublethal cell damage. After 2 hours, H2O2
was removed and OLN93 were allowed to condition fresh
medium for 24 hours (OLN-CMH2O2). Non-damaged
OLN93 cells provided the OLN-CM. The OLN-CMH2O2
and OLN-CM were applied to rMAPC in a 96-well flat
bottom plate (5 × 104 cells/well) for 18 hours resulting in
double-conditioned media (DCM). These media are desig-
nated as DCMH2O2 and DCMnull, respectively. rMAPC
treated with OLN-CMH2O2 and OLN-CM were also proc-
essed for RNA extraction (5 × 105 cells/well per 24-well
plate) to evaluate alterations in gene expression levels of
neurotrophic factors. All the aforementioned conditioned
media were collected and filtered through a 0.45-μm filter.
OLN-93 cells were allowed to adhere in a 96-well flat
bottom plate (5 × 104 cells/well) and exposed to
DCMH2O2 and DCMnull for 6 hours (see Additional file
2). Subsequently, cells were subjected to H2O2-induced
oxidative stress (1 mM, 1.5 mM and 2 mM H2O2 for
24 hours). OLN93 cell viability was determined using
the MTT assay.
Gene expression analysis
rMAPC licensed for 12 hours and rMAPC treated with
OLN93-derived media (OLN-CMH2O2 and OLN-CM)
for 18 hours were processed for gene expression analysis.
Cells were detached, centrifuged and stored in lysis buffer
of RNeasy mini kit (QIAGEN, Venlo, The Netherlands) at
−80 °C until later use.
RNA was isolated with the RNeasy mini kit (QIAGEN)
and was reversely transcribed into complementary DNA
(cDNA) using the Quanta kit (VWR, Leuven, Belgium)
following the manufacturer’s instructions. cDNA was
subsequently used for semi quantitative real-time poly-
merase chain reaction (RT-PCR). Quantitative PCR reac-
tions were performed with a StepOnePlus™ Real-Time
PCR System (Applied Biosystems) in micro-AMP Fast
Optical 96-well reaction plates in a total volume of 10 μl
per reaction. The reaction mix contained 1× Fast SYBR
green master mix (Applied Biosystems), 10 mM of each
primer (designed with Primer 3 [35]; Eurogentec, Liege,
Belgium), nuclease-free water and 12.5 ng of cDNA tem-
plate. The amplification protocol used was the following:
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at 95 °C and 30 seconds at 60 °C, and subsequent
melting-curve analysis. All the primer sequences used
are listed in Additional file 3. Relative quantification of
gene expression was calculated using the 2-ΔΔCt method
[36] and data were normalized to the most stable refer-
ence genes for each experiment according to geNorm
[37]. For visualization of mRNA transcript presence,
PCR amplified products (Hoffmann-La Roche, Basel,
Switzerland) were separated in a 1.5 % agarose gel and
were visualized with ethidium bromide.
Nitrite formation and cytokine release
Supernatants of licensed rMAPC (24 hours) and co-
cultures were collected and release of NO was determined
using the Griess reagent system (Promega, Leuven,
Belgium) following the manufacturer’s instructions.
Absorbance was measured at 550 nm using a micro-
plate reader (Bio-Rad Benchmark, Bio-Rad Laboratories,
Hercules, CA, USA).
IFNγ release was measured in the co-culture super-
natant using Rat IFNγ enzyme-linked immunosorbent
assay (Peprotech) following the manufacturer’s instruc-
tions. Absorbance was measured at 415 nm.
Cell viability assay (MTT)
Cell survival and proliferation was assessed with MTT
assay (Sigma Aldrich). Briefly, 12.5 μl MTT (3-(4,5)-di-
methylthiazol-(−z-y1)-3,5-diphenytetrazoliumronide)
dissolved in 100 μl medium per well was added for 4
hours at 37 °C. After incubation, MTT was removed and
a mixture of 25 μl glycine and 150 μl DMSO/well was
added and the absorbance was determined at 540 nm.
Statistical analysis
Data were analyzed with the GraphPad Prism version
5.00 for Windows, (GraphPad Software, San Diego Cali-
fornia USA [38]) and are presented as mean ± SEM.
D’Agostino and Pearson omnibus normality test was
used to test normal distribution. Parametrical data were
analyzed using unpaired student t test or one way ana-
lysis of variance followed by Dunnett multiple compari-
sons test. Data that did not follow normal distribution
were analyzed using Mann Whitney and Kruskal-Wallis
followed by Dunns multiple comparison test. Differences
with P value ≤0.05 were considered significant.
Results
In vitro licensing does not affect the viability and colony
forming ability of rMAPC
When stem cells are to be used in treating inflammatory
diseases, they will be challenged by a high pro-
inflammatory environment. To evaluate whether inflam-
matory conditions lead to alterations of basic biologicalfunctions, we assessed cell viability and colony formation
ability following in vitro treatment with combinations of
IFNγ, TNFα and IL1β. We show that the viability of
rMAPC was not affected after 24 hours treatment
(Fig. 1a). Similar, the ability of rMAPC to form colonies
was not hampered following pre-treatment with pro-
inflammatory cytokines (Fig. 1b). These findings indicate
that an inflammatory environment does not affect basic
biological functions of rMAPC.
In vitro licensing leads to upregulation of
immunomodulatory genes
The immune suppressive and neuroprotective features
of MSCs are enhanced in the context of neuroinflamma-
tory conditions [23]. We investigated whether the ex-
pression of immunomodulatory molecules of rMAPC is
changed upon in vitro challenge with selected pro-
inflammatory cytokines. Inducible nitric oxide synthase
(iNOS), Ido-1, COX2, programmed death-ligand 1 (PD-
L1) and TNF-stimulated gene 6 protein (TSG-6) have
been proposed as possible mechanisms of immune sup-
pression among others [39–43]. iNOS mRNA levels were
significantly upregulated in rMAPC following IFNγ +
TNFα and TNFα + IL1β treatment (Fig. 2a). In line with
this, NO levels increased in the culture medium (Fig. 2b).
TNFα + IL1β induced the upregulation of TSG-6 and
COX-2 mRNA levels. IFNγ was the main inducer of PD-
L1 as TNFα + IL1β did not show any effect (Fig. 2a).
Ido-1 was only detected after IFNγ + TNFα treatment
(Fig. 2c). COX-1 was decreased following TNFα + IL1β
treatment while heme oxygenase 1 (HO-1) expression was
not altered under any of the treatments (see Additional
file 4).
Hepatocyte growth factor (HGF) has been suggested
to be responsible for neuroprotective and immunomod-
ulatory features of murine MSCs in EAE [44]. In our
study, we detected negligible levels of HGF in rMAPC in
all conditions tested.
The upregulation of inflammatory cytokines by stem
cells could potentially counteract their immune suppres-
sive role and enhance inflammation [27–29]. We found
a minimal but significant upregulation of IFNγ and
TNFα after IFNγ + IL1β and TNFα + IL1β treatment,
respectively. IL-6 expression was not affected under any
of the cytokine combinations (see Additional file 4).
Together, these results suggest that rMAPC, when en-
countering a pro-inflammatory environment, are triggered
to secrete a variety of immunomodulatory molecules.
rMAPC suppress proliferation of encephalitogenic T cells
To elucidate whether rMAPC are suppressive towards T
cells, we performed co-culture experiments with MBP-
specific T cells as a model of encephalitogenic T cells.
MBP-reactive T cells are evident in diverse neurological
Fig. 1 Inflammatory cytokine treatment is not toxic and does not
affect colony formation of rMAPC. a rMAPC were tested for the
formation of colonies following exposure to combinations of
inflammatory cytokines (n = 3 experiments, duplicates per
experiment). The total number of colonies is shown. b Cell
viability was measured after 24-hour treatment with combinations
of pro-inflammatory cytokines. Optical density values are depicted
(n = 4 experiments, triplicates per experiment). CFU-F colony-forming
unit-fibroblasts, IFN interferon, IL interleukin, PBS phosphate-buffered
saline, TNF tumor necrosis factor
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demonstrate that rMAPC potently suppressed T-cell
proliferation in response to MBP even at the lowest ratio
(1:0.5). Increasing the number of rMAPC did not further
enhance the inhibition of T-cell proliferation (Fig. 3a).
The observed effect was not due to cell death, as the
percentage of CD3+7AAD+ cells was not altered (data
not shown). In addition, a decrease in IFNγ was detectedwhen increasing amounts of rMAPC were added
(Fig. 3b). Of note, NO also decreased in a similar way, in
line with the observation that IFNγ induces release of
NO by MAPC (Fig. 2a, b). Activated T cells or thymo-
cytes alone did not produce NO (Fig. 3c).
Inflammatory treatment enhances the suppression of
myelin-specific T-cell proliferation
Next, we investigated whether the pro-inflammatory
cytokine treatment enhances the suppressive properties
of rMAPC towards MBP-specific T cells in line with pre-
vious findings for MSCs [40, 43]. Inhibition of antigen-
specific T-cell proliferation was enhanced when cells
were pre-licensed with either IFNγ + TNFα or TNFα +
IL1β. Of note, pre-licensed rMAPC completely inhibited
the antigen-specific T-cell proliferation reaching the
negative control levels. For IFNγ + IL1β, no increased
suppression was found (Fig. 4a).
To identify the mechanisms involved, we applied se-
lective inhibitors for immune modulatory molecules,
taking into consideration the upregulation of immuno-
modulatory genes reported in this study (Fig. 2a). Specif-
ically, we used inhibitors for iNOS (L-NMMA), COX-2
(indomethacin) and Ido-1 (two isoforms; 1-Mt-L, 1-Mt-
D). Blockade of NO reversed the observed enhancement
of T-cell suppression to the levels observed when MAPC
were not pre-treated with pro-inflammatory cytokines
(Fig. 4b, c). Furthermore, COX-2 inhibition abrogated
the enhanced suppression observed when MAPC were
pre-treated with TNFα + IL1β (Fig. 4c). Ido-1 inhibitors
did not have any reversible effect (Fig. 4b). The inhibi-
tors alone did not have any effect on T-cell proliferation
following exposure to MBP (see Additional file 5). To-
gether, these results demonstrate that rMAPC are able
to suppress the proliferation of encephalitogenic T cells
when restimulated with cognate antigen.
rMAPC acquire a chemoattractive profile following
licensing
T cell chemotaxis is crucial for the suppression of T-cell
proliferation by MSCs [43]. rMAPC constitutively express
mRNA copies of certain chemokines that are massively in-
creased after inflammatory treatment. IFNγ + TNFα led
to a significant induction of four out of five chemokines
tested. TNFα + IL1β upregulated three out of five of the
chemokines, while IFNγ + IL1β only significantly induced
CXCL10 (Fig. 5a, Additional file 4).
To confirm the secretion of chemokines in the culture
medium following inflammatory treatment, we allowed
MBP-specific T cells to migrate towards supernatants of
conditioned medium from licensed rMAPC. Enhanced
T-cell migration was observed towards supernatant of
rMAPC after treatment with TNFα + IL1β and to a
lesser extent after IFNγ + TNFα pre-treatment. No
Fig. 2 (See legend on next page.)
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Fig. 2 Pro-inflammatory cytokines induce the upregulation of immune modulatory genes by rMAPC. a Gene expression of immunomodulatory
molecules by rMAPC following treatment with respective inflammatory cytokines. Fold differences compared to control (PBS treated, dotted line)
are shown. Values represent mean ± SEM from five independent experiments. b Measurement of nitrite in the culture supernatant of rMAPC.
Concentration of nitrite is shown (μM). Mean values (±SEM) from four independent experiments. c Expression of Ido-1 following 12 hours
treatment with respective cytokines. YWHAZ and HMBS were used as loading controls. Representative experiment out of n = 5 performed.
Non-parametrical Kruskal Wallis multiple group comparison test was used followed by Dunns test for differences between groups. Significant
differences with the control condition are indicated with asterisks: *P ≤ 0.05, ** P ≤ 0.01, ***P ≤ 0.001. COX cyclooxygenase, HMBS hydroxymethylbilane
synthase, IFN interferon, ido-1 indoleamine 2,3-dioxygenase 1, IL interleukin, iNOS inducible nitric oxide synthase, PBS phosphate-buffered saline, PD-L1
programmed death-ligand 1, TNF tumor necrosis factor, TSG TNF stimulated gene, YWHAZ 14-3-3 protein zeta/delta
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+ IL1β treated rMAPC was observed (Fig. 5b). These re-
sults match with the massive upregulation of chemokine
mRNA expression (Fig. 5a). Chemokine receptors were
all detected on myelin-specific T cells used in the migra-
tion assay (Fig. 5c).
We conclude that rMAPC are able to exert chemoat-
traction towards T cells when challenged with pro-
inflammatory stimuli.
rMAPC express a set of functional chemokine receptors
Chemokine receptors are potentially involved in MSC
homing when injected in pathological conditions [48].
Therefore, we sought to explore the chemokine receptor
repertoire of rMAPC. We demonstrate that rMAPC ex-
press mRNA levels of CCR1, CCR2, CCR9, CXCR3,
CXCR4, CXCR5, CXCR6, CXCR7 and CX3CR1. rMAPC
did not express detectable levels of CCR3, CCR5, CCR6,
CCR7 and CXCR2 (Fig. 6a).
To confirm the functionality of the receptors expressed,
we explored the migration of rMAPC towards chemokines
known to be expressed during neuroinflammation [49].
rMAPC were able to migrate to all chemokines tested,
namely CCL2, CCL5, CX3CL1, CXCL12α and CXCL10
(Fig. 6b). Generally we observed a dose-dependent in-
crease in chemotaxis in all chemokines used. These results
indicate that rMAPC are attracted to neuroinflammatory
chemokines.
Licensing affects the expression of chemokine receptors
genes and the migration of rMAPC
Systemic inflammation in the periphery could potentially
affect rMAPC migratory behavior and thus dictate mi-
gration towards ongoing inflammation in the CNS and
lymphoid organs. Following licensing we saw a differential
upregulation of chemokine receptors (Fig. 6c, Additional
file 4). Specifically, while IFNγ + TNFα treatment in-
creased only the expression of CXCR3, IFNγ + IL1β
treatment upregulated CCR9, CXCR3, CXCR5 and
CX3CR1. Finally TNFα + IL1β treatment induced the
upregulation of CXCR7 and CX3CR1 while it was the
only condition where CCR3 expression was induced
(data not shown). Of interest, IFNγ + TNFα significantly
downregulated the expression of CCR1.We further assessed the migration of rMAPC following
inflammatory treatment. We observed selective alterations
in the migration pattern of rMAPC upon licensing. In
particular, TNFα + IL1β treatment induced an enhanced
migration of rMAPC towards CCL5, CXCL12α and
CX3CL1, while IFNγ + IL1β enhanced migration to-
wards CXCL10 (Fig. 6d). The observed results correlate
partially with the alterations in the expression of CCR1,
CXCR7, CX3CR1 and CXCR3 following inflammatory
treatment. Of note, IFNγ + TNFα treated rMAPC mi-
grated in a lesser extent towards CCL5, correlating with
the significant downregulation in the expression of
CCR1. The three combinations did not confer signifi-
cant alterations on rMAPC migration towards the vari-
ous concentrations of chemokines, besides the ones
illustrated in Fig. 6d. These results indicate that the in-
flammatory milieu may modify the migratory ability of
rMAPC thereby affecting the expression of certain che-
mokine receptors and subsequent migratory activity.
rMAPC enhance their neuroprotective activity features
when challenged with a neurodegenerative environment
Neurodegeneration-induced secretion of growth factors
by bone marrow-derived stem cells leads to protection
of oligodendrocytes and neurons [34, 44]. To assess po-
tential neuroprotective features of rMAPC in response
to neurodegeneration, we challenged rMAPC with se-
creted factors from the sublethally damaged (H2O2)
oligodendroglia cell line, OLN93 [50]. H2O2 generates
free radicals leading to apoptotic death after oxidative
stress, a situation which is prominent within the CNS
during neurodegenerative events [51]. We demonstrated
that secreted factors released by rMAPC in response to
H2O2-treated OLN93 cells (DCMH2O2) are able to par-
tially protect OLN93 cells in all three concentrations of
H2O2 used. rMAPC-derived soluble factors in response
to non-damaged OLN93 cells (DCMnull) showed no evi-
dence of protecting OLN93 cells from H2O2 damage
(Fig. 7a). rMAPC viability under the influence of OLN-
CMH2O2 was not affected due to possible toxic factors
secreted by early apoptotic cells or H2O2 remnants (data
not shown). OLN93 cells did not show any differences
in cell proliferation when allowed to proliferate for 24
hours in normal culture medium after the pre-treatment
Fig. 3 rMAPC suppress antigen-specific T-cell proliferation and IFNγ
production. a Co-culture of MBP-specific T cells with rMAPC in
increasing ratios (1:0.5 to 1:2). Results are shown as percentage of
proliferation normalized to the positive control (1:0, T cells + MBP).
Mean values ± SEM are from three independent experiments, with
triplicates per experiment. Negative control (T cells without MBP) is
shown as a dotted line. b IFNγ levels measured in the co-culture
supernatants with enzyme-linked immunosorbent assay. Results are
presented as percentages normalized to the positive control (1:0, T
cells + MBP). Mean values ± SEM are from three experiments, with
triplicates per experiment. c Analyses of NO levels in co-culture
supernatants through the measurement of nitrite. Results are shown
as percentages normalized to the lowest ratio in the co-culture
(1:0.5). Mean values ± SEM are from three independent experiments,
with triplicates per experiment. Nitrite was not detected (ND) in the
positive control (1:0, T cells + MBP), or in thymocytes alone + MBP
(not shown). Non-parametrical Kruskal Wallis multiple group comparison
test was used followed by Dunns test for differences between groups.
Significant differences with the control condition are indicated with
asterisks: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. IFN interferon, MBP myelin
basic protein, NO nitric oxide
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soluble factors secreted by rMAPC is actually protective
and does not induce an excessive proliferation resulting
in higher cell numbers. Next, we further characterized
the behavior of rMAPC in the in vitro generated neuro-
degenerative environment. We analyzed the mRNA ex-
pression of neurotrophic factors known to enhance the
survival and proliferation of oligodendrocytes and oligo-
dendrocytes progenitors, as well as those that enhance
myelin formation [44, 52–55]. We demonstrate that
rMAPC when cultured in supernatant derived from sub-
lethally damaged OLN93 cells (OLN-CMH2O2) upregu-
late the expression of the neurotrophic factors VEGFα
and CNTF but not GDNF (Fig. 7c). HGF was not de-
tected under any condition. Collectively, these results in-
dicate that the interaction with neurodegenerative
signals derived by damaged oligodendrocytes enhances
the neuroprotective features of rMAPC.
Discussion
Stem cell transplantation represents a promising thera-
peutic approach to treat neuroinflammatory and neuro-
degenerative disorders such as MS, TBI, SCI and stroke.
In this study, we show that rMAPC, a stem cell popula-
tion similar but distinct to MSCs, possess immunomod-
ulatory and neuroprotective properties which are further
enhanced when challenged with selected neuroinflam-
matory stimuli. These findings point out that MAPC can
be considered as a promising therapeutic option for neu-
roinflammatory and neurodegenerative disorders.
In concordance with other studies, rMAPC exhibit a
low immunogenic profile, being negative for co-
stimulatory molecules and RT-1b. Expression of RT-1a,
though, makes rMAPC prone to lysis by NK cells in case
Fig. 4 Inflammatory licensing of rMAPC leads to enhanced T-cell suppression. a Co-cultures of T cells with rMAPC in the presence of MBP, where
rMAPC were either pre-treated or not (white bars) with different combinations of pro-inflammatory cytokines (IFNγ + TNFα, IFNγ + IL1β, TNFα + IL1β).
Negative control (T cells without MBP) is shown as a dotted line. Asterisks indicate statistical significance compared to the positive control
(1:0, T cells + MBP). Paragraph signs (§) indicate the statistical significance between the pre-treated (assigned bars) and non-treated (white bars)
corresponding ratios. b Application of inhibitors in the co-culture (1:0.5 ratio) after IFNγ + TNFα pre-treatment (black bars). Significant differences
compared to the positive control (1:0, T cells + MBP) are shown with asterisks. Paragraph signs (§) show differences with the non-pre-treated 1:0.5 ratio
(white bar). c Application of inhibitors in the co-culture (1:0.5 ratio) after TNFα + IL1β pre-treatment (striped bars). Significant differences compared to
the positive control (1:0, T cells + MBP) are shown with asterisks. Paragraph signs (§) show differences with the non-pre-treated 1:0.5 ratio (white bar).
Results are shown as mean percentages ± SEM of proliferation normalized to the positive control (1:0, T cells + MBP), from three independent
experiments, with triplicates per experiment. Data were analyzed with non-parametrical Kruskal Wallis multiple group comparison test, followed
by Dunns for differences between the groups. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001; §P ≤ 0.05, §§P ≤ 0.01, §§§P ≤ 0.001. 1-Mt-D 1-methyl-dextro-
tryptophan, 1-Mt-L 1-methyl-levo-tryptophan, IFN interferon, IL interleukin, L-NMMA L-NG-monomethyl arginine citrate, MBP myelin basic protein,
TNF tumor necrosis factor
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genic profile of rMAPC was further confirmed by the
low, if any, increase of pro-inflammatory genes followinglicensing. Upregulation of TNFα by rMAPC should be
investigated further, although TNFα can also act as an
inhibitory mechanism for CD4 T-cell proliferation [56].
Fig. 5 Inflammatory treatment enhances the chemoattractive activity of rMAPC. a Gene expression of chemokines by rMAPC following inflammatory
treatment. Fold differences compared to control (PBS treated, dotted line) are shown. Significant differences with the control condition are indicated
with asterisks. Values represent mean ± SEM from five independent experiments. b Migration of MBP-specific T cells towards supernatants derived from
licensed rMAPC (with defined cytokines combinations). Chemotactic index is shown, which is calculated by dividing the number of migrated T cells
per condition by the number of migrated T cells of the negative control (non-conditioned medium). Results are from three independent experiments,
with duplicates per experiment. c Detection of chemokine receptor mRNA expression in MBP-specific T cells. The genes selected have as ligands the
chemokines upregulated in panel a. The picture is a representative experiment out of a total of three independent experiments. Non-parametrical
Kruskal Wallis multiple groups comparison test was used followed by Dunns test for differences between groups. Significant differences with the
control condition are indicated with asterisks: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. IFN interferon, IL interleukin, rMAPC s/n supernatant derived by naïve
(non-treated) rat multipotent adult progenitor cells, TNF tumor necrosis factor
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hibit T-cell proliferation after polyclonal stimulation or
allogeneic responses [21, 57, 58]. We demonstrate here
that rMAPC effectively suppress proliferation of myelin-
reactive T cells in vitro and that licensing enhances the
suppressive effect of rMAPC. This finding suggests that
transplanted MAPC can suppress the autoantigen-
specific adaptive inflammatory response in MS. In line
with other studies with hMAPC, rMAPC suppressed
IFNγ release from autoreactive T cells in co-culture, in-
dicating an attenuation of Th1 polarization [57].CNS neurodegeneration and peripheral inflammation
represent microenvironments that potentially affect the
behavior of transplanted cells. We show that pro-
inflammatory cytokines markedly increased the expres-
sion of immunomodulatory markers previously reported
for MSCs and hMAPC, such as iNOS, Ido-1, PD-L1,
TSG-6 and prostaglandin E2 (PGE2) [23, 39, 40, 42, 43,
59, 60]. IFNγ-driven upregulation of these molecules in
MAPC and MSCs collectively has been demonstrated
[23, 24, 40, 41, 43, 57]. We now provide evidence that a
combination of inflammatory cytokines and, in particular,
Fig. 6 (See legend on next page.)
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Fig. 6 rMAPC migration is altered following licensing. a Detection of chemokine receptor mRNA in rMAPC. Amplified cDNAs are visualized in a
1.5 % agarose gel. YWHAZ and HMBS were used as loading controls. One representative experiment out of five is shown. b rMAPC migration
towards important MS pathogenesis chemokines. Three different concentrations of chemokines were used in the lower compartment (100, 250 and
500 ng/ml). The percentage of area covered by the migrated cells is shown. Values represent mean ± SEM from four independent experiments, with
duplicates per experiment. Asterisks show statistical significance between the different concentrations of each chemokine and the negative control.
No statistically significant differences were found between the different concentrations for each chemokine. Positive control values showed statistically
significant differences with all the other conditions. Data were analyzed with one way analysis of variance comparison test, followed by Dunnett’s test
for differences between the groups. c Gene expression of chemokine receptors by rMAPC following inflammatory treatment. Fold differences
compared to control (PBS treated, dotted line) are shown. Significant differences with the control condition are indicated with asterisks. Values
represent mean ± SEM from five independent experiments. d rMAPC migration following 12 hours of cytokine pre-treatment. Three different
concentrations of chemokines were used in the lower compartment (100, 250 and 500 ng/ml). Only the statistically significant changes are
shown here. The percentage of area covered by the migrated cells is shown. Values represent mean ± SEM from four independent experiments,
with duplicates per experiment. Asterisks show the statistical significant difference between the pre-treated and not treated (naïve) migrated
fraction towards specific concentrations of each chemokine. All values differ significantly with n.c. Mean of positive control is statistically significant
to all the other conditions. Data were analyzed with one way analysis of variance comparison test, followed by Dunnett’s test for differences between
the groups. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. IFN interferon, IL interleukin, n.c. negative control, p.c. positive control, rMAPC rat multipotent adult
progenitor cells, TNF tumor necrosis factor
Fig. 7 Neurodegeneration enhances the neuroprotective features of rMAPC. a Neuroprotection assay where OLN93 cells were pre-treated (with
the indicated (double) conditioned media and then three concentrations of H2O2 were added (pos. control). Optical densities are shown (±SEM)
from five experiments. Negative control (dotted line) represents OLN93 cells without damage insult. One way analysis of variance followed by
Dunnet’s test for multiple comparisons between groups was used. b OLN93 cells were pre-treated for 5 hours with rMAPC double conditioned
media (DCM) and then allowed to proliferate for 24 hours. Optical densitites are shown (±SEM), n = 5 experiments. c rMAPC gene expression of
neurotrophic factors (VEGFα, CNTF, GDNF) when treated with OLN-CMH2O2 and OLN-CM. Expressions were relatively quantified against the
expression of YWHAZ and CycA. The fold differences are shown in comparison to OLN-CM (±SEM) from five experiments. Mann Whitney t-test
was used for comparisons between two groups. Significant differences are shown with asterisks: *P ≤ 0.05, ** P ≤ 0.01, ***P ≤ 0.001. CM
conditioned medium, CNTF ciliary neurotrophic factor, GDNF glial cell line-derived neurotrophic factor, OLN med OLN93 medium, VEGF vascular
endothelial growth factor
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the increase of iNOS, TSG-6 and COX-2 mRNA tran-
scripts. We demonstrate that the increase of NO and
PGE2 is functionally involved in the suppression of T-cell
proliferation by licensed rMAPC as suppression was abro-
gated when iNOS and COX-2 were inhibited in the co-
cultures.
While PGE2 has already been reported to partially
underlie the suppressive effect of mMAPC on T-cell
proliferation [21, 41], we now provide evidence that NO
is crucial in this process as well. Notably, other studies
using mMAPC have excluded PGE2 and NO as possible
mechanisms for the modulation of alloreactive T-cell re-
sponses [21, 61]. Moreover, human and rat MAPC have
been reported to modulate alloreactive T-cell responses
by an Ido-dependent mechanism [57, 58]. Jacobs et al.
showed that IFNγ pre-treatment of hMAPC did not
confer an additional suppressive effect as it was already
of a great extent without pre-licensing [57]. Overall,
there is a pluripotency and species-related variation re-
garding the mechanisms involved in T-cell suppression,
as is apparent for MSCs as well [62, 63].
We found that licensing of rMAPC markedly in-
creased the expression of a large number of chemokines,
such as CXCL2, CXCL10, CCL2, CCL5 and fractalkine.
These chemokines are well known for their ability to at-
tract encephalitogenic CD4+ T cells in the context of
neuroinflammation [64–67], as well as CD8+ T cells
[68]. The ability of stem cells to migrate towards inflam-
matory chemokines and to attract leukocytes is a crucial
aspect of their potential therapeutic use. For instance, an
IFNγ-mediated increase in chemokine release by murine
MSCs, such as CXCL10, is key to their immunomodula-
tory properties [43]. In line with this chemoattractive
transcriptional profile, we demonstrated that rMAPC ef-
fectively attracted myelin-specific T cells, especially when
challenged with IFNγ + TNFα and TNFα + IL1β. In this
project we only assessed the capacity of rMAPC to at-
tract T cells. Others have shown that licensing enhances
the chemoattractive ability of human MSCs towards
other immune cells and, mainly, neutrophils [69]. Future
studies should determine whether MAPC also attract
other immune cell subsets that play an important role in
inflammatory pathophysiology, such as monocytes and
dendritic cells. Increased attraction of other immune cell
types such as macrophages, for instance, would be cru-
cial for the immunomodulatory mechanisms of MAPC,
as it has already been demonstrated that hMAPC sup-
press their classically activated phenotype in vivo [18].
In addition to their ability to attract T cells, we charac-
terized rMAPC regarding their migratory profile. We
observed that rMAPC were able to migrate towards che-
mokines typical for a neuroinflammatory environment.
Of interest, the motility of rMAPC towards thesechemokines was further enhanced following licensing,
except of the CCL2/CCR1 interaction following IFNγ +
TNFα treatment. Overall, these results point out the po-
tential of rMAPC in transplantation experiments where
inflammation is already established. Directed injection of
NSCs within the CNS in the EAE model showed that in-
flammation triggered the migration of the transplanted
cells towards the white matter tracts, with CXCL12α
and CCL2 being important inflamed tissue-derived che-
moattractive stimuli [70]. Furthermore, in other neu-
roinflammatory models, both peripheral- and CNS-
targeted injected stem cells are being attracted by local
sites of inflammation [71]. While the lack of expression
of CCR7 could limit the migration of rMAPC to lymph-
oid organs, previously reported experimental set up with
intravenous administration of hMAPC showed no real
obstacle [19]. This points out that other molecules in
addition to chemokine receptors are implicated [72].
Overall, these features highlight the migratory potential
of rMAPC when injected either in the periphery or
within the CNS.
MSCs and NSCs possess neuroprotective features
which are induced from inflamed CNS microenviron-
ment [4, 34]. Our findings show that rMAPC that are
exposed to sublethally damaged OLN93 cells gain neu-
roprotective properties. This suggests that damaged oli-
godendrocytes release mediators that promote the
neuroprotective capacity of rMAPC. Similar findings
have been reported for rat MSCs [34]. The fact that
rMAPC increase their expression of trophic factors con-
firms this notion. It has already been suggested that hu-
man and rodent MAPC provide neuroprotection and
vascular regeneration in vivo through the secretion of
trophic factors [73–75]. Oligodendrocytes in normal
appearing white matter (NAWM) seem to actively par-
ticipate in immune regulation within the CNS during
MS pathology as they are elevating the expression of
transcription factors such as STAT-6 and STAT-4, which
are important for the activation of anti- and pro-
inflammatory pathways, respectively [76]. IL-4 and IL1β,
which have been detected in oligodendrocytes in MS
NAWM, could prime rMAPC in the same way as do the
combinations of pro-inflammatory cytokines. In this
way, rMAPC could be effectively triggered by damaged
oligodendrocytes or even neurons to secrete trophic fac-
tors and thus provide neuroprotection.
Conclusions
MAPC possess the required properties needed to con-
sider the development of a therapeutic scheme for neu-
roinflammatory disorders such as MS, TBI and SCI, as
was established previously for MSCs [6, 7, 77]. We show
that rMAPC are lowly immunogenic and possess numer-
ous potential mechanisms which could facilitate MAPC
Ravanidis et al. Stem Cell Research & Therapy  (2015) 6:176 Page 15 of 17action, even if they cannot transdifferentiate towards
damaged CNS cells. While the microenvironment in
neuroinflammatory disorders is likely more complex, we
show that typical pro-inflammatory cytokines and medi-
ators released by damaged oligodendrocytes strongly
enhance the immunomodulatory properties of rMAPC.
Apart from affecting T cells and oligondendrocytes,
MAPC may also affect other immune and CNS-resident
cell types that are important drivers of neuroinflamma-
tion, such as macrophages, microglia and astrocytes.
Future studies should define the impact of (licensed)
rMAPC on these cell types. Collectively, our findings
suggest that MAPC represent an interesting therapeutic
tool for the treatment of neuroinflammatory disorders.
Yet, future experiments should reinforce the notion that
MAPC can reduce neuroinflammation and neurodegen-
eration in animal models of MS, TBI and SCI [18–20].Additional files
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